Technical Analysis for IVX - Invion Ltd  

Grade Last Price % Change Price Change
F 0.200 9900.00% 0.198
IVX closed down 33.33 percent on Tuesday, November 19, 2024, on approximately normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.
Earnings due: Nov 28
*** please verify all earnings dates ***
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 9900.00%
Fell Below 50 DMA Bearish 9900.00%
Boomer Buy Setup Bullish Swing Setup 9900.00%
Narrow Range Bar Range Contraction 9900.00%
Wide Bands Range Expansion 9900.00%
Gapped Down Weakness 9900.00%
Jack-in-the-Box Bearish Bearish Swing Setup 6566.67%
Crossed Above 20 DMA Bullish 6566.67%
Crossed Above 50 DMA Bullish 6566.67%
180 Bullish Setup Bullish Swing Setup 6566.67%

   Recent Intraday Alerts

Alert Time
3x Volume Pace 3 days ago
Down 10% 3 days ago
Gapped Down (Full) 3 days ago
Down 1 ATR 3 days ago
2x Volume Pace 3 days ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Invion Ltd   Description

Invion Limited is a clinical-stage life sciences (drug development) company. The Company is engaged in the completion of clinical development programs and targeted business development programs associated with its approximately three drug assets, such as INV102 (nadolol), INV103 (ala-Cpn10) and INV104 (zafirlukast). It focuses on the development of treatments for opportunities in chronic inflammatory and respiratory disease. INV102 (nadolol) is a beta adrenergic biased ligand targeted to treat chronic inflammatory airway diseases via the reversal of mucous metaplasia in the airway epithelium. INV104 (zafirlukast) is a leukotriene receptor antagonist (LTRA) that reduces inflammation, constriction of the airways, and the build-up of mucus in the lungs. INV103 (ala-Cpn10) is a modified, naturally occurring human protein, which has been proposed as a founding member of the Resolution Associated Molecular Pattern (RAMPs) family hypothesized to maintain and restore immune homeostasis.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Chemistry Disease Diseases Life Sciences Protein Reversal Drug Development Helium Chemical Compounds Organic Compounds Omeo Inflammation Respiratory Disease

Is IVX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 0.008
52 Week Low 0.002
Average Volume 5,302,042
200-Day Moving Average 0.004
50-Day Moving Average 0.002
20-Day Moving Average 0.002
10-Day Moving Average 0.002
Average True Range 0.001
RSI (14) 47.37
ADX 37.96
+DI 25.000
-DI 9.722
Chandelier Exit (Long, 3 ATRs) 0.001
Chandelier Exit (Short, 3 ATRs) 0.004
Upper Bollinger Bands 0.003
Lower Bollinger Band 0.002
Percent B (%b) 0.36
BandWidth 63.636
MACD Line 0.000
MACD Signal Line 0.000
MACD Histogram -0.0001
Fundamentals Value
Market Cap 11.07 Million
Num Shares 5.54 Billion
EPS 0.00
Price-to-Earnings (P/E) Ratio -10.00
Price-to-Sales 17.40
Price-to-Book 11.21
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.002
Resistance 3 (R3) 0.002 0.002 0.002
Resistance 2 (R2) 0.002 0.002 0.002 0.002
Resistance 1 (R1) 0.002 0.002 0.002 0.002 0.002
Pivot Point 0.002 0.002 0.002 0.002 0.002
Support 1 (S1) 0.002 0.002 0.002 0.002 0.002
Support 2 (S2) 0.002 0.002 0.002 0.002
Support 3 (S3) 0.002 0.002 0.002
Support 4 (S4) 0.002